|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
|
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | ||||
| Accounts receivable, net | ||||
| Inventory | ||||
| Due from Biogen | ||||
| Restricted cash | ||||
| Other current assets | ||||
| Total current assets | ||||
| Property, plant and equipment, net | ||||
| Intangible assets, net | ||||
| Goodwill | ||||
| Deferred tax assets | ||||
| Other long-term assets | ||||
| Total assets | ||||
| LIABILITIES AND EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | ||||
| Accrued expenses and other current liabilities | ||||
| Current portion of line of credit | ||||
| Due to True North Therapeutics equityholders | ||||
| Due to Biogen | ||||
| Total current liabilities | ||||
| Long-term liabilities | ||||
| Other long-term liabilities | ||||
| Deferred tax liabilities, net | ||||
| Contingent consideration | ||||
| Total liabilities | ||||
| Equity: | ||||
| Common stock, $0.001 par value (shares authorized of 800,000,000 at December 31, 2017 and 1,000 at December 31, 2016; shares issued and outstanding of 108,203,439 at December 31, 2017 and 1,000 at December 31, 2016) | ||||
| Additional paid-in capital | ||||
| Retained earnings | ||||
| Accumulated other comprehensive loss | ||||
| Total equity | ||||
| Total liabilities and equity |
Loading...
